154 related articles for article (PubMed ID: 12730763)
1. Comparison of calcium and alfacalcidol supplement in the prevention of osteopenia after kidney transplantation.
Berczi C; Asztalos L; Kincses Z; Balogh A; Löcsey L; Balázs G; Lukács G
Osteoporos Int; 2003 Jun; 14(5):412-7. PubMed ID: 12730763
[TBL] [Abstract][Full Text] [Related]
2. [Changes in calcium metabolism after kidney transplantation].
Berczi C; Asztalos L; Kincses Z; Országh I; Löcsey L; Balogh A; Balázs G
Magy Seb; 2001 Apr; 54(2):95-100. PubMed ID: 11339099
[TBL] [Abstract][Full Text] [Related]
3. Cyclosporine bone remodeling effect prevents steroid osteopenia after kidney transplantation.
Westeel FP; Mazouz H; Ezaitouni F; Hottelart C; Ivan C; Fardellone P; Brazier M; El Esper I; Petit J; Achard JM; Pruna A; Fournier A
Kidney Int; 2000 Oct; 58(4):1788-96. PubMed ID: 11012914
[TBL] [Abstract][Full Text] [Related]
4. Pamidronate therapy as prevention of bone loss following renal transplantation.
Fan SL; Almond MK; Ball E; Evans K; Cunningham J
Kidney Int; 2000 Feb; 57(2):684-90. PubMed ID: 10652047
[TBL] [Abstract][Full Text] [Related]
5. Effect of paricalcitol on mineral bone metabolism in kidney transplant recipients with secondary hyperparathyroidism.
Borrego Utiel FJ; Bravo Soto JA; Merino Pérez MJ; González Carmelo I; López Jiménez V; García Álvarez T; Acosta Martínez Y; Mazuecos Blanca MA
Nefrologia; 2015; 35(4):363-73. PubMed ID: 26306956
[TBL] [Abstract][Full Text] [Related]
6. High-normal calcium (1.35 mmol/l) dialysate in patients on CAPD: efficient and safe long-term control of plasma calcium, phosphate, and parathyroid hormone.
Bro S; Brandi L; Olgaard K
Nephrol Dial Transplant; 1996 Aug; 11(8):1586-91. PubMed ID: 8856216
[TBL] [Abstract][Full Text] [Related]
7. Bone mineral disorders in pediatric and adolescent renal transplant recipients.
Derakhshan A; Behbahan AG; Lotfi M; Omrani GH; Fallahzadeh MH; Basiratnia M; Al-Hashemi GH
Pediatr Transplant; 2011 Jun; 15(4):367-75. PubMed ID: 21429060
[TBL] [Abstract][Full Text] [Related]
8. Prevention of bone loss in children receiving long-term glucocorticoids with calcium and alfacalcidol or menatetrenone.
Rianthavorn P; Pisutikul K; Deekajorndech T; Tepmongkol S; Suphapeetiporn K
J Pediatr Endocrinol Metab; 2012; 25(3-4):307-12. PubMed ID: 22768661
[TBL] [Abstract][Full Text] [Related]
9. [Hemodialysis with 2.5 mEq/L of calcium in relative hypoparathyroidism: long-term effects on bone mass].
Sánchez Perales MC; García Cortés MJ; Borrego FJ; Fernández Martínez S; Borrego J; Pérez del Barrio P; Liébana A; Pérez Bañasco V
Nefrologia; 2000; 20(3):254-61. PubMed ID: 10917002
[TBL] [Abstract][Full Text] [Related]
10. Allogeneic bone marrow transplantation is associated with a preferential femoral neck bone loss.
Buchs N; Helg C; Collao C; Chapuis B; Slosman D; Bonjour JP; Rizzoli R
Osteoporos Int; 2001; 12(10):880-6. PubMed ID: 11716193
[TBL] [Abstract][Full Text] [Related]
11. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
12. Positive effects of a chicken eggshell powder-enriched vitamin-mineral supplement on femoral neck bone mineral density in healthy late post-menopausal Dutch women.
Schaafsma A; van Doormaal JJ; Muskiet FA; Hofstede GJ; Pakan I; van der Veer E
Br J Nutr; 2002 Mar; 87(3):267-75. PubMed ID: 12064336
[TBL] [Abstract][Full Text] [Related]
13. Determinants of reduced bone mineral density and increased bone turnover after kidney transplantation: cross-sectional study.
Kusec V; Smalcelj R; Cvijetić S; Rozman B; Skreb F
Croat Med J; 2000 Dec; 41(4):396-400. PubMed ID: 11063762
[TBL] [Abstract][Full Text] [Related]
14. Superiority of alfacalcidol over plain vitamin D in the treatment of glucocorticoid-induced osteoporosis.
Ringe JD; Dorst A; Faber H; Schacht E; Rahlfs VW
Rheumatol Int; 2004 Mar; 24(2):63-70. PubMed ID: 14513268
[TBL] [Abstract][Full Text] [Related]
15. Low-dose alfacalcidol controls secondary hyperparathyroidism in predialysis chronic kidney disease.
Reichel H
Nephron Clin Pract; 2010; 114(4):c268-76. PubMed ID: 20090369
[TBL] [Abstract][Full Text] [Related]
16. Intravenous alfacalcidol once weekly pulse therapy for secondary hyperparathyroidism in hemodialysis patients.
El-Shafey EM; Alsahow AE; El-Nagar GF; Ezzat A
Ren Fail; 2011; 33(3):329-33. PubMed ID: 21401359
[TBL] [Abstract][Full Text] [Related]
17. Etidronate prevents high dose glucocorticoid induced bone loss in premenopausal individuals with systemic autoimmune diseases.
Nakayamada S; Okada Y; Saito K; Tanaka Y
J Rheumatol; 2004 Jan; 31(1):163-6. PubMed ID: 14705236
[TBL] [Abstract][Full Text] [Related]
18. Bone marker and bone density responses to dopamine agonist therapy in hyperprolactinemic males.
Di Somma C; Colao A; Di Sarno A; Klain M; Landi ML; Facciolli G; Pivonello R; Panza N; Salvatore M; Lombardi G
J Clin Endocrinol Metab; 1998 Mar; 83(3):807-13. PubMed ID: 9506732
[TBL] [Abstract][Full Text] [Related]
19. Treatment of osteopenia and osteoporosis in renal transplant children and adolescents.
El-Husseini AA; El-Agroudy AE; El-Sayed MF; Sobh MA; Ghoneim MA
Pediatr Transplant; 2004 Aug; 8(4):357-61. PubMed ID: 15265162
[TBL] [Abstract][Full Text] [Related]
20. Preventing bone loss in renal transplant recipients with vitamin D.
El-Agroudy AE; El-Husseini AA; El-Sayed M; Ghoneim MA
J Am Soc Nephrol; 2003 Nov; 14(11):2975-9. PubMed ID: 14569109
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
